Will a second CRISPR-based gene therapy receive FDA approval in 2026?

The US FDA must approve a second distinct CRISPR/Cas9-based gene therapy (beyond Casgevy for sickle cell/beta-thalassemia) for any indication before December 31, 2026. Based on FDA approval announcements.